Aquestive Therapeutics, Inc. (AQST)
Stock Price:
$4.61 USD
0.03 (0.66%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
154.82M |
| Revenue (ttm) |
48.73M |
| Net Income (ttm) |
-68.05M |
| Shares Out |
33.58M |
| EPS (ttm) |
-2.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$4.61 |
| Previous Close |
$4.58 |
| Change ($) |
0.03 |
| Change (%) |
0.66% |
| Day's Open |
4.61 |
| Day's Range |
4.50 - 4.70 |
| Day's Volume |
494,599 |
| 52-Week Range |
1.41 - 10.00 |
More Stats
| Market Cap |
154.82M |
| Enterprise Value |
184.25M |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
33.58M |
| Float |
27.65M |
| EPS (basic) |
-2.51 |
| EPS (diluted) |
-2.47 |
| FCF / Share |
-1.69 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.63M |
| Short Ratio |
1.07 |
| Short % of Float |
8.38% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.18 |
| PB Ratio |
n/a |
| Revenue |
48.73M |
| Operating Income |
-53.46M |
| Net Income |
-68.05M |
| Free Cash Flow |
-56.59M |
| Net Cash |
-29.43M |
| Net Cash / Share |
-0.88 |
| Gross Margin |
66.18% |
| Operating Margin |
-109.69% |
| Profit Margin |
-139.60% |
| FCF Margin |
-116.12% |
| ROA |
-50.44% |
| ROE |
-3,347.45% |
| ROIC |
-86.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$17.50*
(279.61% upside)
Low
8.00
Current: 4.61
High
31.00
Target: 17.50
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 52.61 | 67.43 | 66.92 | 51.79 |
| Revenue Growth | -21.98% | 0.77% | 29.22% | - |
| Gross Profit | 32.25 | 46.44 | 47.10 | 35.41 |
| Operating Income | -52.67 | -48.94 | -0.11 | -0.95 |
| Net Income | -66.25 | -61.38 | -8.94 | -9.60 |
| Shares Outstanding | 25.36 | 20.73 | 121 | 119 |
| Earnings Per Share | -2.61 | -2.96 | -0.09 | -0.10 |
| Operating Cash Flow | -60.21 | -12.99 | 5.82 | -8.18 |
| Capital Expenditures | -0.66 | -1.82 | -2.07 | -0.98 |
| Free Cash Flow | -60.87 | -14.82 | 3.76 | -9.15 |
| Cash & Equivalents | 49.33 | 60.60 | 17.38 | 9.21 |
| Total Debt | 60.34 | 47.20 | 45.51 | 38.65 |
| Net Cash / Debt | -11.01 | 13.40 | -28.13 | -29.44 |
| Assets | 78.48 | 86.85 | 43.12 | 39.39 |
| Liabilities | 84.60 | 76.77 | 69.61 | 96.59 |
| Book Value | -6.12 | 10.08 | -68.60 | -57.20 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aquestive Therapeutics, Inc. |
| Country |
United States |
| Employees |
232 |
| CEO |
Keith J. Kendall |
Stock Information
| Ticker Symbol |
AQST |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AQST |
| IPO Date |
July 25, 2018 |
Description
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.